Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044951 | 0.86 | ATR (0.39) | PRMT1AAK1METAP1SMN1; SMN2MAPT | |
| SCHEMBL15511586 | 0.81 | AAK1 (0.39) | AAK1METAP1NPC1RAB9A | |
| SCHEMBL31441184 | 0.80 | AAK1 (0.43) | AAK1METAP1 | |
| SCHEMBL30118370 | 0.79 | SMN1; SMN2 (0.45) | AAK1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL13833547 | 0.79 | SMN1; SMN2 (0.45) | AAK1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL23483654 | 0.79 | CYP17A1 (0.42) | AAK1METAP1 | |
| SCHEMBL21262159 | 0.79 | ATR (0.41) | AAK1METAP1 | |
| SCHEMBL29918800 | 0.79 | CYP17A1 (0.42) | AAK1METAP1 | |
| SCHEMBL12341867 | 0.79 | HTT (0.41) | PRMT1GAASMN1; SMN2MAPTNPC1 | |
| SCHEMBL17336445 | 0.78 | AAK1 (0.44) | AAK1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-3983389-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220098167-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM16A LTD (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2020249957-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | Enterprise Therapeutics Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | PRMT1 1020/4885GAA 575/4885AAK1 1371/4885 |
| US-20220098167-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM109, SLC16A1, CFTR | PRMT1 2014/4885GAA 432/4885AAK1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.